期刊
FUTURE ONCOLOGY
卷 18, 期 26, 页码 2967-2978出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2022-0226
关键词
DCC-2618; GIST; INTRIGUE; INVICTUS; KIT; PDGFR; resistance mutation; ripretinib
类别
资金
- Merck Sharp Dohme
- GlaxoSmithKline
The management of gastrointestinal stromal tumors has played a crucial role in advancing targeted therapies for solid tumors. Imatinib has been a successful first-line therapy, but the development of resistance necessitates the use of other treatments. Ripretinib is a switch-control tyrosine kinase inhibitor that specifically targets resistance mutations, and its molecular rationale and clinical use are discussed in this article.
Over the past 20 years, the management of gastrointestinal stromal tumors has acted as an important model in the advancement of molecularly targeted therapies for solid tumors. The success of imatinib has established it as a lasting therapy in the management of early-stage and advanced disease in the first-line setting. Imatinib resistance inevitably develops, resulting in the need for further lines of therapy. Ripretinib is an orally administered switch-control tyrosine kinase inhibitor, specifically developed to target both primary and secondary KIT and PDGFR alpha resistance mutations. Herein, the authors discuss the molecular rationale, the preclinical evidence and the clinical use of ripretinib in the treatment of gastrointestinal stromal tumors in the advanced stages of disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据